Investors Buy Shares of Johnson & Johnson (JNJ) on Weakness
Investors purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading on Monday. $178.45 million flowed into the stock on the tick-up and $65.26 million flowed out of the stock on the tick-down, for a money net flow of $113.19 million into the stock. Of all companies tracked, Johnson & Johnson had the highest net in-flow for the day. Johnson & Johnson traded down ($0.55) for the day and closed at $123.22
Several analysts have recently commented on JNJ shares. Standpoint Research started coverage on shares of Johnson & Johnson in a research report on Friday, May 20th. They set a “sell” rating and a $94.00 price objective on the stock. Leerink Swann reiterated an “outperform” rating and issued a $140.00 price target (up from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Argus lifted their price target on shares of Johnson & Johnson from $116.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, April 20th. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Friday, June 3rd. Finally, RBC Capital Markets reiterated an “outperform” rating and issued a $133.00 price target (up from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $119.30.
The firm has a market capitalization of $332.46 billion and a PE ratio of 22.65. The firm has a 50 day moving average of $123.21 and a 200 day moving average of $113.39.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Equities analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 19th. Investors of record on Friday, August 5th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 0.95%.
In related news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Gary J. Pruden sold 9,735 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the sale, the vice president now owns 43,630 shares of the company’s stock, valued at $5,062,388.90. The disclosure for this sale can be found here.
Several hedge funds and institutional investors have bought and sold shares of the stock. Heritage Wealth Advisors raised its position in Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock valued at $1,021,000 after buying an additional 317 shares during the last quarter. Lourd Capital LLC increased its position in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock worth $1,142,000 after buying an additional 851 shares in the last quarter. Eidelman Virant Capital increased its position in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock worth $1,193,000 after buying an additional 1,231 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Johnson & Johnson by 9.9% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 13,032 shares of the company’s stock worth $1,339,000 after buying an additional 1,179 shares in the last quarter. Finally, Private Capital Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $1,428,000.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.